Clinical trial · Interventional
Persistent Organic Pollutants and Breast Cancers (POPCASE)
Prospective, Multicenter, Epidemiological Case-control Study, to Establish a Possible Correlation Between Persistent Chemical Contaminants (POPs) and Breast Cancer.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Exposure to certain classes of chemical contaminants, including certain persistent organic pollutants (POPs) with a character of endocrine disruptors, could be one of the factors that lead to increase incidence of breast cancer in the Western world . However, the causal role of POPs in the onset of breast cancer remains nowadays unproven. Preliminary epidemiological studies on the impact of these environmental factors in breast cancer etiology have ignored the critical periods of exposure. Similarly, they have considered a limited number of pollutants (not including possible joint or synergistic effects between individual compounds) and did not distinguish the different breast cancer subtypes may have different etiologies or even of genetic susceptibility factors (POP polymorphism of detoxification enzymes). Thus, POPCASE study examines the association between the presence of breast cancer and the levels and exposure profiles to a group of POPs measured in adipose tissue (AT) and blood, in particular using spectrometric methods developed by the team LABERCA (Nantes, France). These internal levels of POPs (organochlorine pesticides, dioxins, PCBs, brominated flame retardants) will be measured both quantitatively (tissue concentrations) and qualitative (relative proportions of different pollutants sought).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Breast cancer surgery | Procedure | — | UNRESOLVED |
| plastic surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm A = Breast Cancer surgery
- description
- Arm A : women undergoing breast cancer surgery.
- interventionNames
- Procedure: Breast cancer surgery
- type
- OTHER
- label
- Arm B = Control (plastic surgery)
- description
- Arm B : women undergoing breast surgery for the purpose of plastic surgery
- interventionNames
- Procedure: plastic surgery
Primary outcomes (1)
- measure
- correlation between the individual risk of breast cancer and persistent chemical contaminants
- timeFrame
- 10 years after surgery
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Women ≥ 18 and \<75 years 2. According to the arm: * Arm A: histologically confirmed diagnosis of invasive breast cancer (only), unilateral or bilateral, outside off recurrence and relapse. Patients who have been supported for a contralateral breast cancer can be included if a period of at least 2-years between the last systemic treatment of inclusion in the study. * Arm B: Any woman operated on for breast plastic surgery (breast lift and breast reduction cure only) 3. Performance status (WHO) ≤ 1 5\. Patient affiliated to a social security scheme, 6. Patient who signed and dated informed consent form 7. Arm A only: unifocal lesion 8. Arm A only: Clinical stage M0 Exclusion Criteria: 1. Patient with uncontrolled infection 2. Patient pregnant or lactating 3. Patient with a viral infection (HIV, Hepatitis B, Hepatitis C) 4. Patient cannot be regularly monitored for psychological reasons, social, family or geographical. 5. Patient Private of liberty or under a guardianship authority / curatorship. 6. Arm A only: Patient to benefit from neoadjuvant therapy for breast cancer 7. Arm A only Patient with metastatic breast cancer 8. Arm A only Patient diagnosed cancer in situ (intra ductal) 9. Arm A only Patient with BRCA1 or BRCA2 known 10. Arm B only: previous breast plastic surgery, regardless of the type of intervention
References
Publications (0)
Data not yet available